“
“We analyzed natal dispersal characteristics for 79 red wolves in the first long-term dispersal analysis for this species. Variables

analyzed included straight-line dispersal distance, duration, timing, age, direction, and evidence of natal habitat preference induction of dispersers. We compared these values during a time when the population was increasing (1990–1998) to a period when the numbers had leveled off (1999–2007) and stabilized. We found no difference in average dispersal distance, duration or age between the two periods, and no gender bias in these characteristics. Yearlings/adults dispersed shorter distances (29.5 km) than pups (42.5 km) from 1999 to 2007 and decreased their dispersal distances during this period. After 1999, Selinexor molecular weight dispersals occurred 11 months of the year (compared with 7 months in 1990–1998), and the peak in pup dispersal timing shifted from December to January. The peak in dispersal timing was also significantly XAV-939 datasheet later for pups than yearlings/adults in 1999–2007. Dispersal direction was not random and there was a preference for a westward dispersal direction, attributed to the avoidance of water and a preference for agriculture. Natal habitat preference induction was also evident in dispersers during both time periods. “
“Finely tuned adjustment

of an individual’s phenotype can offer substantial fitness benefits when it is closely matched with environmental change. For instance, prey may be safeguarded against unnecessary costs to growth or development when their responses to temporally variable predation risk include plastic anti-predator defences. Yet, the correspondence between perceived predation risk and related responses should differ between behavioural and morphological phenotypes when risk fluctuates because behaviour can be modified quickly, whereas morphological phenotypes require time to build. Theoretical models predict intermediate expression when risk fluctuates rapidly relative to the time required to mount a response, whereas traits that can be modified relatively quickly should more closely track current

conditions. Using a tadpole-dragonfly Fossariinae larva system, we sought to compare the expression of behavioural and morphological defences following exposure to constant versus variable predation risk. By varying the pattern and total duration of predator cue exposure, but not cue concentration, we quantified phenotypic plasticity and trait reversibility. Our results show that strong behavioural responses were limited to early ontogeny but closely matched current level of risk. The morphology of prey experiencing a weekly changing predator environment was intermediate to that of prey in the no-predator and constantly exposed treatments. Yet, prey exposed to a predator environment for the same total duration as the weekly changing environment, but in a different exposure pattern, was morphologically unresponsive to the onset of predation risk.

12C). Treatment with the PPARγ antagonist significantly decreased the Insig-1 expression level in quiescent HSCs in a dose-dependent manner (Fig. 8C). This study showed that increased cholesterol

intake accelerated liver fibrosis in the two mouse models of NASH without affecting the degree of hepatocellular injury or Kupffer cell activation. The exacerbation of liver fibrosis mainly involved FC accumulation in HSCs, which increased TLR4 protein levels through suppression of the endosomal-lysosomal degradation pathway of TLR4, down-regulated the expression of the TGFβ pseudoreceptor Bambi, and thereby sensitized the cells to TGFβ-induced activation. This study also showed that EX 527 ic50 FC loading of HSCs is not sufficient Ivacaftor molecular weight to induce activation but serves to enhance activation initiated by TGFβ. These results are compatible with our previous finding[3] that showed that FC accumulation in HSCs increased membrane TLR4 levels; suppressed the HSC expression of Bambi, the TLR4 target gene[14]; and subsequently exaggerated liver fibrosis in mouse models of liver fibrosis. This study also helped to elucidate the main mechanisms by which HSCs are sensitive to

FC accumulation. The SREBP2-mediated feedback system, which plays a major role in maintaining cellular cholesterol homeostasis,[5, 6] was disrupted in HSCs; this disruption could be attributed to high expression of Scap and no expression of Insig-2 in these cells. This could explain why the HC diet significantly reduced SREBP2 signaling in hepatocytes but not in HSCs, and resulted in enhanced FC accumulation in HSCs. Furthermore, HSC activation sensitized these cells to FC accumulation. Repression of PPARγ signaling underlies HSC transdifferentiation.[15] In the present study, the level of PPARγ decreased along with the activation of HSCs.

The suppression of PPARγ signaling Interleukin-3 receptor in activated HSCs decreased the cellular expression of Insig-1, which resulted in enhancing the disruption of the SREBP2-mediated cholesterol-feedback system. This could partly explain why SREBP2 signaling in HSCs was enhanced, along with their activation, although FC accumulation continued to increase. In addition, the decreased PPARγ signaling in activated HSCs also enhanced SREBP2 expression and signaling, resulting in enhanced expression of the LDLR, the SREBP2 target gene, in HSCs. As SREBF2 is a bifunctional locus encoding SREBP2 and miR-33a,[10] suppression of PPARγ signaling also increased the level of miR-33a in HSCs, in turn suppressing the levels of NPC1 and ABCA1 (data not shown), which are negatively regulated by miR-33a.[10] These results showed that HSC activation enhanced FC accumulation, in part because of the increased LDLR level and the decreased NPC1 and ABCA1 levels. The present results suggest that these characteristic mechanisms in HSCs could sensitize the cells to enhanced FC accumulation after increased intake of cholesterol and/or activation of HSCs.

For the purpose of the present study, all five definitions were applied at 3, 6, and 12 months after UDCA therapy and evaluated using the same endpoint, which was the occurrence of adverse outcome as defined by at least one of the following events: liver-related death, liver transplantation, or complications of cirrhosis (ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma). Data were censored at the time of death or liver transplantation for the patient who died or underwent transplantation, and at the time of presenting with a cirrhosis-related

complication Staurosporine datasheet or of last follow-up for the living nontransplanted patients. If a living nontransplanted patient developed more than one cirrhosis-related complication during follow-up, data were censored at the time of the first presentation of cirrhosis-related complications. Comparisons between biochemical variables before and after

3, 6, or 12 months of UDCA treatment were performed using the Wilcoxon signed-rank test for paired data. Survival rates without adverse outcome were estimated using the Kaplan-Meier method. The buy HM781-36B effects of baseline factors and of biochemical responses to UDCA on survival rate were estimated using the Cox proportional hazards regression model. The average hazard ratio and 95% confidence interval were used to quantify the strength of the statistical links between the tested variables and survival. The sensitivity (Se), specificity Alectinib cost (Sp), positive (PPV) and negative (NPV) predictive values, and positive and negative (NLR) likelihood ratios were calculated

for all definitions to assess their performance for prediction of long-term outcome. Quantitative data are expressed as the mean ± SD and qualitative data as a percentage. All analyses were two-sided, and P < 0.05 was considered statistically significant. The statistical package SPSS 16.0 (SPSS Inc, Chicago, IL) was used to perform the analysis. A total of 187 patients (94% females; age, 51 ± 9 years) met the inclusion criteria. Biochemical data were available in 128 patients for the third month after UDCA treatment, 145 patients for the sixth month, and 157 patients for 1 year. To take full advantage of the available data, we used all of them for analyses. Table 1 shows the characteristics of the patients at baseline and after 1 year of UDCA therapy. Figure 1 shows the evolution of ALT, AST, ALP, GGT, serum bilirubin, albumin, and immunoglobulin M (IgM) levels within the first year of UDCA treatment. A prominent decline in the serum activities of ALP, GGT, AST, and ALT was noted in the first three months (P < 0.0001), which was accompanied by a significant decrease of bilirubin (P < 0.0001) and IgM (P < 0.0001) and elevation of albumin (P < 0.0001).

A headache-free group served as a control. Methods.— Data on headache and psychological trait variables

(eg, internalizing symptoms), behavioral factors (eg, physical activities), and socio-environmental factors (eg, life events) were gathered by questionnaire. Logistic regression analyses were conducted with headache types (MIG, tension-type, and non-classifiable headache) as dependent variables. selleck chemical Results.— The pattern of correlations was largely congruent between the headache disorders. Associations were closest regarding maladaptive psychological traits (in particular internalizing symptoms with an odds ratio > 4 regarding MIG) compared with socio-environmental factors and particularly the behavioral factors. Unfavorable psychological traits and socio-environmental strains demonstrated distinctly stronger associations with MIG than tension-type headache and explained more variance in the occurrence of pediatric headache disorders than parental headache. buy Crizotinib Sex-specific analyses showed similarities as well as differences regarding the correlations, and in general, the associations

were stronger in girls than boys. Conclusions.— A common path model as posited by several researchers in the field may explain the parallelism in biopsychosocial vulnerability regarding the different headache disorders. “
“Reversible cerebral vasoconstriction syndrome (RCVS) is a cerebrovascular disorder with a clinical picture that continues to be refined. It has presented to multiple subspecialties over the past several decades, enough bringing with it many questions regarding risk factors, diagnosis, and management. Answers have been forthcoming but many questions remain. RCVS presents with recurrent, secondary thunderclap headaches and predominantly affects young women. The mechanism of vasoconstriction is unclear, but there has been speculation regarding a hyperadrenergic state. Diagnosis

requires physician awareness, vascular imaging, and knowledge of the differential. The hallmark of its diagnosis is reversibility. Management is empiric, usually with calcium-channel blockers, as there are no controlled treatment trials for RCVS. Randomized controlled trials are needed. “
“(Headache 2010;50:451-458) Objective.— We aimed to report 10 new cases of epicrania fugax (EF), showing their clinical features and therapeutic responses. Background.— Epicrania fugax has been recently described as a paroxysmal head pain starting in a focal area located at a posterior cranial region and rapidly spreading forward to the ipsilateral eye or nose along a linear or zigzag trajectory. In some patients the pain is followed by ocular or nasal autonomic features. In the prior series, 1 patient got pain relief with anesthetic blockades, while another patient improved with carbamazepine. Methods.

White/non-Hispanics and Hispanics had a higher prevalence of current HCV infection (14% and 15%, respectively) compared with black/non-Hispanics (7%) (odds ratio [OR]=2, 95% confidence interval [CI]=1.47-2.93 and OR=2, 95% CI=1.9-2.9). Ever having

injected drugs was the strongest risk factor for HCV infection (OR=20.6, CI=16.4-26.0). Of the participants with current infection, 85% attended their first medical appointment; as of April 2014, over 50% remained in care. Discussion: The community-based testing model successfully identified a large number of persons with HCV infection and linked a high proportion to care. The high prevalence of HCV infection among baby boomers supports the NY Testing Law and CDC recommendations. Expanding this Panobinostat model to more settings with high-risk populations will aid in successfully identifying and linking HCV positive

individuals into care. Disclosures: Eric J. Rude – Grant/Research Support: Vertex, Merck, Bristol Myers AZD3965 in vivo Squibb, Orasure, Janssen, Gilead, Kadmon, Boehringer-Ingelheim, Abbott, Genentech The following people have nothing to disclose: Mary Ford, Ashly Jordan, Nirah Johnson, Holly Hagan, Fabienne Laraque, Jay K. Varma Background: The hepatitis C virus (HCV) first identified in 1989 is a highly infectious blood borne virus that has spread extensively globally, especially among people who inject drugs (PWID). The current study uses pooled biological and behavioral data from 8 individual prospective studies of PWID to describe HCV incidence over time (1985-2011), across locales (U.S., Canada, the Netherlands, and Australia). Methods: We used life table methods to estimate the incidence of HCV infection within the first two years of follow-up by locale, and estimated rate ratios to compare infection rates between acetylcholine locales. Results: Of 5,248 participants, 2,891 (55%) tested HCV negative at enrollment; of these, 2,197 (42%) were followed prospectively for a median of 1.2 years (Interquartile range [IQR]: 0.5, 2.6 years); median age at study entry was 25 (IQR, 21, 28), the majority were white (69%) and male (64%). The drug injected

most often included heroin (50%), [meth]amphetamines (18%), cocaine (12%), and other opioids (7%) and varied by locale. During 5,259 person-years observation (pyo) of follow-up, 673 became infected for an estimated overall incidence of 12.8/ 100 pyo (95% CI: 12, 14). HCV incidence was highest within the first 5 years of study observation (14.0/pyo; 95% CI 12, 15). Historical trends in HCV infection rates (≤2 years follow-up) decreased for participants in the Dutch and Australian cohorts, increased for Canadian cohorts, and remained steady for American cohorts across 1985-2011 (table 1). Incidence (≤2 years follow-up) was highest among cohort participants in the U.S. (27.7 / pyo; 95% CI 24, 31), followed by Canada and Australia at 23.6/pyo (95% CI 18, 29) and 12.

1C). The PHB2 protein level was also reduced, but to a lesser degree, to 30% to 40% of controls in the liver and hepatocytes (Fig. 1C). From the time of birth, there is variability in the weight and health of the KO mice. 15% of the pups (115/768) died before weaning (3 weeks old). Although most were not genotyped, of the ones that died before weaning and were examined, all were liver-specific KOs. KOs that survived past 3 weeks weighed less than WT control littermates and

this difference persisted up to 14 weeks of age (Supporting Figs. 2 and 3). The relative liver to body weight was higher in the KO mice (Table 1). At 3 weeks of age, many KO mice appeared ill, and liver injury is biochemically evident (Table 1). Liver injury is confirmed histologically by marked necrosis Talazoparib price and inflammation seen throughout the liver learn more (Fig. 2B,C). There is also bile duct metaplasia (Fig. 2D), anisocytosis of hepatic nuclei (Fig. 2E), and positive staining for OV-6, an oval cell marker (Fig. 3B), and glutathione S-transferase Pi (GSTP) (Fig. 3D), a preneoplastic marker in the 3-week-old KO liver. Mat1a KO mice have higher hepatic triglyceride levels11

and develop steatohepatitis.12 This prompted us to measure lipid levels in the liver-specific Phb1 KO mice. Liver-specific Phb1 KO mice have elevated plasma cholesterol levels, but their hepatic cholesterol levels and both plasma and hepatic triglyceride levels were unchanged from WT controls (Table 1). As the mice grew older, by 14 weeks hepatic nodules can be seen in some liver sections but not

very on gross examination (Fig. 2F). By 38 weeks, many KO livers stain positive for alpha-fetoprotein (AFP) (Fig. 3F). Because PHB1 is a mitochondrial chaperone protein, we examined mitochondrial morphology by EM. Supporting Fig. 4A,B shows that mitochondria in the 3-week-old KO liver appear swollen and many have no discernible cristae. Positive 4-hydroxynonenal (4-HNE) staining from increased lipid peroxidation in the KO liver, as compared to WT control liver (Supporting Fig. 4C,D), is consistent with impaired mitochondrial function. As the KO mice grew older, there was progressive apoptosis, as shown by activated caspase-3 staining (Fig. 4, top row), persistent proliferation as indicated by proliferating cellular nuclear antigen (PCNA) staining (Fig. 4, middle row), and progressive fibrosis on reticulin staining (Fig. 4, bottom row). Based on histologic examination, no frank cancer was noted in eight KO mice on a normal diet by 14 weeks. However, by 20 weeks, all mice have multiple liver nodules on gross examination of the liver (Fig. 5B); between the ages of 35 and 46 weeks 38% (5/13 mice; 1/5 male, and 4/8 female) have multifocal HCC (Fig. 5C,D). Because Phb1 KO mice develop HCC, we next compared PHB1 protein expression in normal primary human hepatocytes to that of human HCC cell lines Huh-7 and HepG2.

Caput medusae is the appearance of distended and engorged paraumbilical veins that radiate from the umbilicus across the abdomen to join systemic veins. It takes its name from Medusa, the mythical gorgon learn more of Greek mythology, because of its similarity to Medusa’s snakelike hair. The pathogenesis of PVSA remains controversial. It may be congenital or acquired as a result of cirrhosis, PH, pancreatitis, trauma, or surgery.1 However, the lack of proportion between the rates of PH and PVSA suggests

that cirrhosis and PH may be contributory but not essential to the development of PVSA.2 In this case, PVSA was considered to be congenital, and PH was the result of portal vein thrombosis, which occurs in approximately 30% of PVSA cases because of turbulent flow and stasis1 and can lead to PH with clinically severe consequences. Therefore, although most PVSA cases are asymptomatic and require

no treatment, when PVSA is associated with thrombosis, PH, rupture, or compression BGB324 of the common bile duct or duodenum, surgical intervention is indicated. “
“A 16-year old female was referred for further evaluation of long common channel documented on MRCP. Five months ago, she developed colicky pain and fever. Blood chemistry showed these results—AST 185 IU/L, ALT 256 IU/L, alkaline phosphatase 378 U/L, gamma glutamyl transpeptidase 397 U/L, total bilirubin 2.4 mg/dL, and direct bilirubin

1.8 mg/dL. Several tiny stones at the distal common bile duct were observed on CT and were removed completely under ERCP. Four months later, she developed upper abdominal pain and had an amylase level of 1536 IU/L. A CT scan showed pancreatic swelling and peripancreatic infiltration, suggesting acute pancreatitis. She recovered after 4 days of supportive care. A retrospective review of the MRCP revealed a 33 mm-long common channel (Fig. 1, double arrow), prominent Santorini’s duct crossing common bile duct, and a short communicating duct (Fig. 1 arrow) between common channel and Santorini’s duct (Fig. 1). These findings were documented on nearly the ERCP. There was no abnormal finding suggesting gallbladder cancer or choledochal cyst. The final diagnosis was made as AUPBD with incomplete type of pancreas divisum. AUPBD is a congenital anomaly, characterized by a junction of the bile duct and pancreatic duct outside of the duodenal wall. It was hypothesized that AUPBD develops as a result of a mis-arrangement of the pancreaticobiliary system. On the other hand, pancreas divisum results from an abnormal fusion of the dorsal and ventral pancreas in utero. Co-incidence of both developmental anomalies may be possible, but the exact incidence rate has not yet been reported. AUPBD and pancreas divisum were observed in up to 1.5% and 7.5% of patients undergoing ERCP respectively.

Hematoxylin

and eosin (H&E) stainings of 3-μm paraffin sections were used to evaluate basic histomorphology of the specimens, especially the portal and lobular amount of inflammatory cells (score 0-3 for negative to strong infiltration) and signs of regeneration/degeneration of hepatocytes (e.g., cytoplasmic volume, nuclear polymorphism, and thickness of liver cell plates as well as hepatic apoptotic bodies).23 Content of extracellular collagen was measured by the amount of chromotrope-aniline blue (CAB) in the portal tract and hepatic lobule (score 0-3 for negative to strong staining).24 Proliferating Enzalutamide nmr cell nuclear antigen (PCNA) and desmin staining were performed on an autostainer system (Dako), using the EnVision Detection System (Dako, Glostrup, Denmark), and developed using diaminobenzidine as the chromogen substrate (Roche Molecular Biochemicals, Mannheim, Germany), according to the manufacturer’s instructions. To highlight neutrophil granulocytes in liver tissue, naphtol AS-D chloroacetate esterase enzyme (NASD) histochemistry was used.25 Liver slices were stained for cluster of differentiation (CD)3 and forkhead box protein 3 (Foxp3) and developed with the PolapKit (Zytochem, Las Condes, Chile). Images were evaluated per mm2 (PCNA) or high-power field (400× magnification) using ImageAccess Enterprise software (version

9; Imagic, Glattbrugg, Switzerland). Histological quantification PI3K Inhibitor Library cell assay was performed by a pathologist. Results were analyzed using the Student’s t test, if two groups were compared; in addition, for analysis of real-time RT-PCR, logarithmized data and Welch’s t test were used. All data Dichloromethane dehalogenase in this study are expressed as a mean ± standard error of the mean. P ≤ 0.05 was considered significant. HO-1 induction or overexpression have been shown to interfere with liver damage in mouse models of acute inflammation and apoptosis.7, 8 We have investigated the effects of HO-1 induction on chronic hepatic inflammation and fibrosis in Mdr2ko mice. Nine weeks of HO-1 induction in Mdr2ko mice (weeks 5-14 of lifespan) decreased plasma ALT levels, which increased over the first 22 weeks of lifespan (Fig. 1A, open bars). Significant

improvement was observed for at least 8 weeks beyond treatment (Fig. 1A, closed bars). HO-1 induction by CoPP in liver tissue was detectable on messenger RNA (mRNA) (Supporting Fig. 1A) and protein level (Supporting Fig. 1B) and did not alter hematocrit values (Supporting Fig. 1C). Likewise, isolated PHs and HSCs of Mdr2ko mice showed HO-1 induction after CoPP incubation (Supporting Fig. 1D). IHC staining of liver samples obtained at 12 weeks of age revealed reduced periportal and lobular inflammation in CoPP-treated mice (Fig. 1B). HO-1 induction significantly reduced the expression of TNFR1 and 2, whereas TNF expression in whole liver tissue was increased in Mdr2ko mice, compared to FVB background control (data not shown), but was not altered by HO-1 induction (Fig. 1C).

4a). When the DR0101 Stem Cell Compound Library ic50 tetramer was loaded with FVIII2218–2237, staining of the T-cell clones was at background levels, demonstrating the specificity of the clones for the DR0101-FVIII2194–2213 peptide complex (Fig. 4b). The antigen specificity of the T-cell clones

was further tested by proliferation assays. Each T-cell clone proliferated in response to FVIII2194–2213 presented by DR0101 (Fig. 5). The amount of proliferation was dose-dependent over the range of peptide concentrations tested (0.1–10 μm). The stimulation indices (ratios of measured proliferation/background proliferation) were highly significant, ranging from 62 to 248 at 0.1 μm peptide concentration for the six clones. The T-cell clones also proliferated in response to a peptide with the haemophilic sequence, FVIII2194–2213, 2201P, but at significantly reduced levels. However, this proliferation was above the background levels established using an irrelevant peptide, FVIII519–538. This stimulation by the haemophilic (missense) sequence was in contrast to the behaviour of clones isolated from the clinical inhibitor subject IV-1, which did not proliferate in response to the haemophilic peptide [33]. The T cells from haemophilic subject IV-3 that were stimulated with peptide pool 2 were next stained using DR1104 tetramers carrying FVIII2202–2221 and then

single-cell sorted into 96-well plates as described above. Cells in 13 wells expanded sufficiently to be tested for tetramer binding, and cells in four of these wells were tetramer-positive (Fig. 6). The binding avidity of these T-cell clones for the DR1104 tetramer Selleckchem Barasertib loaded with FVIII2202–2221 was low (Fig. 6a) compared with that of the clones shown in Fig. 4a. These T-cell clones did not bind to the DR1104 tetramer loaded with FVIII2186–2205 (Fig. 6b), verifying the specificity

of these T-cell clones for a peptide adjacent to the missense substitution A2201P. None of these T-cell clones expanded well under conditions routinely used for expansion of human Selleckchem Nutlin-3 T-cell clones, so they could not be further analysed or cryo-preserved. The presence of FVIII-responsive T cells in subject IV-2, who did not have an inhibitor but whose T-cell response was highly similar to that of his brother, raised the possibility that he might have circulating inhibitory antibodies, albeit at a sub-clinical level. To address this possibility, IgG was Protein G-purified from his plasma and Bethesda assays were carried out for serial dilutions of the concentrated IgG samples. At 10 mg mL−1, his IgG sample had an inhibitor titre of 1 BU mL−1, demonstrating a trace level of circulating inhibitory antibody. Our previous study of T-cell responses to FVIII peptides in a mild haemophilia A inhibitor subject with missense substitution FVIII-A2201P established a powerful approach to identify HLA-DR-restricted T-cell epitopes in FVIII [33].

Lancet 2001; 358(9283): 718–723. 46  van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; Palbociclib molecular weight 40: 1421–1425. 47  Delaugerre C, Marcelin AG, Thibault V et al. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents

Chemother 2002; 46: 1586–1588. 48  Lacombe K, Gozlan J, Boyd A et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B in HIV-HBV-coinfected patients. Antivir Ther 2008; 13: 705–713. 49  Zhao SS, Tang LH, Dai XH et al. Comparison of the this website efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virol J

2011; 8: 111. 50  Tujios SR, Lee WM. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013; 29: 250–256. 51  Schildgen O, Schewe CK, Vogel M et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004; 18: 2325–2327. 52  Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008: 48: 590–598. 53  Piroth L, Pol S, Lacombe K. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53:1006–1012. 54  Schmutz G, Nelson M, Lutz T et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951–1954. 55  Lee K, Chang S, Su Y et al. Clinical And Virologic Outcomes After Switch To Tenofovir/lamivudine Of HIV-infected Patients with Hepatitis B Virus (HBV) Resistance to Lamivudine Resveratrol in an Hyperendemic Area for HBV

Infection. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2012 [Abstract H-218]. 56  Wiens A, Lenzi L, Venson R et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2013; 33: 144–151. 57  Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008; 48: 1062–1069. 58  Matthews G. The management of HIV and hepatitis B coinfection. Curr Opin Infect Dis 2007; 20: 16–21. 59  Matthews GV, Seaberg EC, Avihingsanon A et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013; 56: e87–e94. 60  Chan HL, Hui AJ, Chan S et al.